IROD

Pathology-Targeted EP4 Agonism Reverses Fibrosis in a Rat Model of DMD

Duchenne muscular dystrophy (DMD) presents a critical therapeutic gap in adolescent patients, where fibro-fatty muscle replacement and depletion of the regenerative niche render existing interventions insufficient. Prostaglandin E2 signaling through the EP4 receptor stimulates muscle regeneration, but systemic off-target effects have limited clinical translation of EP4 agonism. We evaluated irodanoprost (IROD), a bone-targeted prodrug of an EP4-selective agonist, in a DMD rat model using...